UK at a glance
- Population
- 69.5 million 2025
- Life expectancy at birth
- 81.4 years, 2024
- People aged 65 and over
- 19.7 % of people, 2025
- Health spending per person
- 5,860 US$ per person, 2024
- Doctors
- 3.30 per 1,000 people, 2023
UK Exosome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Application, Source, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$44.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $6.6 Mn | — | — |
| 2025 (base) | $8.2 Mn | +$1.5 Mn | — |
| 2026 (forecast) | $10.1 Mn | +$1.9 Mn | +23.1% |
| 2027 (forecast) | $12.4 Mn | +$2.3 Mn | +51.5% |
| 2028 (forecast) | $15.3 Mn | +$2.9 Mn | +86.5% |
| 2029 (forecast) | $18.8 Mn | +$3.5 Mn | +129.6% |
| 2030 (forecast) | $23.1 Mn | +$4.3 Mn | +182.7% |
| 2031 (forecast) | $28.5 Mn | +$5.3 Mn | +248% |
| 2032 (forecast) | $35.1 Mn | +$6.6 Mn | +328.4% |
| 2033 (forecast) | $43.1 Mn | +$8.1 Mn | +427.3% |
| 2034 (forecast) | $53.1 Mn | +$10.0 Mn | +549.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Exosome therapeutics use tiny vesicles released by cells to carry drugs or healing signals, for cancer, inflammation and regenerative medicine.
Key segments of the exosome Therapeutics market include application (Drug Delivery, Regenerative Medicine and Diagnostics) and source (Stem Cell-Derived, Plant-Derived and Engineered).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the exosome Therapeutics market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the exosome Therapeutics market. Payers are still working out how to pay for one-time cures.
The exosome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for exosome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.
What doctors and scientists are doing in Exosome Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.
[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
From our blog
UK · 2 shared keywords
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
Medical Devices · UK
Digital Health · UK
Healthcare Services · UK
Healthcare Services · UK
Medical Devices · UK
Healthcare Services · UK